Zhen Liu

Zhen Liu


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
JLJiashun Li
Jiashun Li
AAAinikaer Abulaiti
Ainikaer Abulaiti
DLDeyu Li
Deyu Li
YZYan Zhao
Yan Zhao
PWPaerhati Wahafu
Paerhati Wahafu
ZLZhen Liu
Zhen Liu
Objective: BCMA- or GPRC5D-directed CD3 bispecific antibodies are important T-cell–redirecting therapies for relapsed/refractory multiple myeloma (RRMM). We evaluated their efficacy, safety, and certainty of evidence. Methods: We searched the Cochrane Library, Embase, PubMed, Scopus, and Web of Science from inception to February 5, 2026. Prospective clinical trials and real-world studies of BCMA×CD3 or GPRC5D×CD3 bispecific antibodies in RRMM with extractable efficacy and safety data were included. Main efficacy outcomes were progression-free survival (PFS), stringent complete response (sCR), complete response (CR), complete response or better (≥CR), very good partial response or better (≥VGPR), and overall response rate (ORR). Safety outcomes included cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), infection, neutropenia, anemia, and thrombocytopenia. Single-arm proportional meta-analyses, sensitivity analyses, meta-regression, and subgroup analyses were performed using STATA/MP 18.0. Methodological quality and evidence certainty were assessed using MINORS and GRADE, respectively. Results: Fifteen studies, including 17 independently extractable cohorts and 1,900 patients, were analyzed. The pooled PFS was 8.76 months (95% CI, 6.82–11.13). The pooled rates of sCR, CR, ≥CR, ≥VGPR, and ORR were 28.7%, 18.1%, 38.2%, 51.0%, and 65.9%, respectively. The pooled incidences of CRS, ICANS, infection, grade ≥3 infection, neutropenia, and grade ≥3 neutropenia were 67.5%, 9.7%, 60.3%, 38.3%, 54.7%, and 42.6%, respectively. MINORS showed moderate-to-high methodological quality. GRADE showed low-to-very low certainty of evidence. Conclusion: BCMA- or GPRC5D-directed CD3 bispecific antibodies showed clinically meaningful antitumor activity in RRMM. However, current evidence is mainly from single-arm trials and retrospective real-world studies, and certainty of evidence remains low to very low. These findings should be interpreted cautiously, with particular attention to infection and neutropenia in clinical practice.

28 September 2026 in Langenbeck's Archives of Surgery
Verified
Journal Article
Open access
PDF file
JLJiashun Li
Jiashun Li
ZWZheng Wang
Zheng Wang
DLDeyu Li
Deyu Li
MMMaerdan Maimaitiming
Maerdan Maimaitiming
GLGuohua Li
Guohua Li
MYMaihemuti Yakufu
Maihemuti Yakufu
Objective A systematic comparison of the clinical efficacy and safety between Unilateral Biportal Endoscopy (UBE) and Percutaneous Endoscopy (PE) in the Treatment of Cervical Spondylotic Radiculopathy (CSR). Method Computerized searches were conducted in PubMed, Cochrane Library, Web of Science, Embase, China National Knowledge Infrastructure(CNKI), Wanfang Data, VIP Chinese Science and Technology Periodical Database(VIP) and other relevant journals to collect clinical studies comparing UBE and PE for the treatment of CSR, from the inception of each database until September 2025. Two researchers independently performed literature screening and data extraction, and assessed the quality of the included studies using the Newcastle-Ottawa Scale (NOS). Meta-analysis was carried out with RevMan 5.4 software on the following outcomes: operative time, intraoperative blood loss, visual analog scale (VAS) scores for neck and upper limb pain, Neck Disability Index (NDI), MacNab excellent-good rate, and complications. The search strategy flowchart follows the PRISMA 2020 flow diagram. Result A total of 6 studies were ultimately included, comprising 222 patients in the UBE group and 205 patients in the PE group. Meta-analysis results demonstrated that, compared to the PE group, the UBE group had a shorter operative time [MD = -13.72, 95% CI (-15.80, -11.64), P < 0.00001], but a greater amount of intraoperative blood loss [MD = 17.09, 95% CI (2.59, 31.58), P = 0.02]. Regarding pain and functional recovery, the UBE group showed superior upper limb VAS scores at the 3-month postoperative follow-up [MD = -0.14, 95% CI (-0.26, -0.01), P = 0.03] compared to the PE group. However, there were no statistically significant differences between the two groups in VAS scores at the remaining time points (postoperative 3 days, 1, 6, and 12 months), NDI scores at all time points, the MacNab excellent-good rate, or the overall complication rate. Conclusion Both UBE and PE are safe and effective minimally invasive techniques for treating CSR, with comparable long-term outcomes. UBE has a shorter operative time but relatively greater intraoperative blood loss. At the 3-month postoperative upper limb VAS assessment, the UBE group demonstrated a statistical advantage, though the clinical significance of this difference requires further evaluation. Surgical selection should be individualized based on specific pathological characteristics, patient factors, and surgeon expertise.

21 September 2026 in BMC Medical Imaging
Verified
Journal Article
Open access
PDF file
ZWZheng Wang
Zheng Wang
ZLZhen Liu
Zhen Liu
JLJiashun Li
Jiashun Li
YAYiliyasi Aboduaini
Yiliyasi Aboduaini
AAAinikaer Abulaiti
Ainikaer Abulaiti
GLGuohua Li
Guohua Li
Rotator cuff tear is a common cause of shoulder pain and functional impairment, and its accurate identification is of great significance for clinical treat